Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology

Case Report

Published on 04 Dec 2025

Case Report: Exercise-associated changes of leukocyte gene expression in statin-associated myopathy

in Cardiovascular and Smooth Muscle Pharmacology

Galyna Bondar
Abhinandan Das Mahapatra
Irina Silacheva
Tra-Mi Bao
Thomas Vu
Stephanie Su
Adrian Hairapetian
Ananya Katappagari
Liana Galan
Joshua Chandran

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1695543

2,703 views

Original Research

Published on 03 Dec 2025

Gallic acid attenuates diabetic cardiomyopathy by inhibiting ferroptosis and protecting mitochondria via the TSPO/FTMT pathway

in Cardiovascular and Smooth Muscle Pharmacology

Chenchao Zou
Huaihan Xu
Fajia Hu
Yuxian Yu
Lanxiang Liu
Xiuqi Wang
Zheyu Zhang
Huaxi Zou
Jichun Liu
Huang Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1661144

901 views

Review

Accepted on 30 Nov 2025

Probucol: Revisiting as a Multi-faceted Therapeutic Agent in Atherosclerosis

in Cardiovascular and Smooth Muscle Pharmacology

Sha Li
Hui-Hui Liu
Ruixia Xu
Jian-Jun Li

Frontiers in Pharmacology

374 views

Original Research

Published on 28 Nov 2025

Association between ranolazine therapy and cognitive decline in elderly patients with ischemic heart disease

in Cardiovascular and Smooth Muscle Pharmacology

Giandomenico Severini
Giuseppe Armentaro
Velia Cassano
Valentino Condoleo
Carlo Alberto Pastura
Alberto Panza
Carlo Fuoco
Sofia Miceli
Vanessa Teresa Fiorentino
Maria Perticone

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1664988

681 views

Review

Published on 28 Nov 2025

Targeting L-arginine/NO/cGMP/KATP pathway by phytochemicals: therapeutic applications and clinical perspectives

in Cardiovascular and Smooth Muscle Pharmacology

Seyede Zahra Hosseini
Fatemeh Abbaszadeh
Seyede Darya Alavi
Mohammad Mehdi Gravandi
Roshanak Amirian
Sajad Fakhri
Javier Echeverría

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1708659

807 views

Original Research

Published on 27 Nov 2025

The complications of cyclosporine a in pediatric use and its effectiveness in treating pediatric congenital heart diseases-a meta analysis in combined with a retrospective clinical study

in Cardiovascular and Smooth Muscle Pharmacology

Yiting Xue
Siqi She
Sijuan Sun
Junxian Chen
Lincai Ye
Yanhui Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1727970

845 views

Review

Published on 27 Nov 2025

Echocardiographic assessment and new advances of right ventricle function in rats with pulmonary hypertension

in Cardiovascular and Smooth Muscle Pharmacology

Weijie Wang
Ming Ren
Dianxiang Lu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1682105

638 views

Original Research

Accepted on 25 Nov 2025

Jaranol: a compound with therapeutic activity against pathological cardiac remodelling via multi-target inhibition of the Snai3/TLR2 and NF-κB signaling pathways

in Cardiovascular and Smooth Muscle Pharmacology

Yao Zhang
Nan Li
Shiqi Chu
Heqing Fu
Xiaowen Yang
Huimin Xia
Yunfeng Xiao
Zhibin Xiao
Jing Liu
Yu Dong

Frontiers in Pharmacology

177 views

General Commentary

Published on 21 Nov 2025

Commentary: Hyperoside alleviates myocardial ischemia-reperfusion injury in heart transplantation by promoting mitochondrial fusion via activating the Stat3-Tom70-Opa1 pathway

in Cardiovascular and Smooth Muscle Pharmacology

Qin Yang
Yingjie Liu
Xinzheng Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1724858

478 views

Original Research

Accepted on 20 Nov 2025

Preventive effect of small molecule active substances on septic cardiomyopathy after abdominal trauma: A systematic review and meta-analysis

in Cardiovascular and Smooth Muscle Pharmacology

Gen Ouyang
Neng Wang
Yujuan Liu
Chuang Yang
Peng Zeng
Tao Gong
Lu Tao
Ying Zheng
Guiying Ye
Hong Li

Frontiers in Pharmacology

Original Research

Published on 19 Nov 2025

The potential mechanism of celastrol attenuating atherosclerosis by promoting macrophage autophagy via AMPK/ULK1 pathway

in Cardiovascular and Smooth Muscle Pharmacology

Jiao Li
Yanrong Zhao
Yanfang Qi
Yafang Chen
Yue Liu
Linlin Fang
Zhenying Zhou
Liping Wei
Qi Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1700663

778 views

Review

Published on 17 Nov 2025

Endoplasmic reticulum oxidoreductin 1α as a potential therapeutic target in diseases: from oxidative protein folding to pathophysiological mechanisms

in Cardiovascular and Smooth Muscle Pharmacology

Fang He
Xiaoyue Ge
Xiaohui Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1709284

793 views

Original Research

Published on 17 Nov 2025

Terminal complement inhibition in atypical haemolytic uremic syndrome: a single-centre experience

in Cardiovascular and Smooth Muscle Pharmacology

Valentin D. Mocanu
Bogdan M. Sorohan
Elena G. Micu
Sonia Bălănică
Bogdan Obrişcă
Roxana A. Jurubiță
Camelia A. Achim
Adrian C. Lungu
Cristina S. Căpuşă
Gabriel Mircescu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1683188

1,463 views

Original Research

Accepted on 14 Nov 2025

Gut Microbiota-Dependent Anti-Inflammatory Mechanisms of Berberine in Ameliorating Hypertension: Role of SCFAs, LPS Reduction, and STAT3 Signaling

in Cardiovascular and Smooth Muscle Pharmacology

Wang Shanshan
Yaqian Hu
Xin Li
Yanhua Ou
Jinling Chen
Chen Yuhan
Jingyi Chen
Kunran Bai
Fangwen Xu
Xingyi Wang

Frontiers in Pharmacology

416 views

Review

Published on 10 Nov 2025

The unmet promise: a critical review of antioxidant strategies in myocardial ischemia-reperfusion injury and the path towards precision medicine

in Cardiovascular and Smooth Muscle Pharmacology

Hao Chen
Yutao Tang
Pan Ren
Wenbin Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1693441

1,234 views

Original Research

Published on 10 Nov 2025

A novel bioactive peptide-peptoid hybrid of alpha-calcitonin gene-related peptide protects against pressure-overload induced heart failure

in Cardiovascular and Smooth Muscle Pharmacology

Ambrish Kumar
Sarah Deloach
Lernix Williams
Donald J. DiPette
Jay D. Potts

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1692472

1,250 views

Case Report

Published on 07 Nov 2025

Rifampicin-induced challenges in managing endocrine hypertension and primary aldosteronism: a case report and literature review

in Cardiovascular and Smooth Muscle Pharmacology

Xiaoxiao Song
Minyue Jia
Hanxiao Yu
Zhichao Dong
Kai Cheok
Xin Pan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1678430

1,280 views

Original Research

Published on 31 Oct 2025

Agonizing GABABR suppresses GLP-1RA’s chronotropic effect and reduces post-myocardial infarction arrhythmogenesis

in Cardiovascular and Smooth Muscle Pharmacology

Run Qi
Zhang Jingjing
Gu Hongchang
Li Chenyu
Hu He
Li Juan
Zhao Yuqin
Wu Xiaolin

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1616181

2,854 views

Original Research

Published on 30 Oct 2025

Efficacy and influencing factors analysis of SGLT2 inhibitors in treating heart failure following acute myocardial infarction

in Cardiovascular and Smooth Muscle Pharmacology

Haiping Du
Hui Xu
Jinwei Bao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1693420

1,267 views

Original Research

Published on 27 Oct 2025

Risk of post-polypectomy bleeding and thromboembolic events during colonoscopy in patients on continued or interrupted antiplatelet therapy: a pooled analysis

in Cardiovascular and Smooth Muscle Pharmacology

Nan-Nan Shen
Jun-Hong Ma
Hua Qian
Yong-Ping Fu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1660871

791 views

Original Research

Published on 24 Oct 2025

Quantitative assessment of the usability of electromechanical human-based modelling and simulation to replace Langendorff isolated rabbit heart experiments in the preclinical setting

in Cardiovascular and Smooth Muscle Pharmacology

Maxx Holmes
Hector Martinez-Navarro
Marcel Mohr
Jean-Marie Chambard
Veronique Ballet
Eva Vermersch
Ambroise Garry
Friedemann Schmidt
Blanca Rodriguez

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1671199

1,404 views

Original Research

Published on 21 Oct 2025

The interaction of AB-680, a CD73 inhibitor, with NBTI, a nucleoside transporter inhibitor, on the adenosinergic control of atrial contractility

in Cardiovascular and Smooth Muscle Pharmacology

Ignac Ovari
Agnes Boglarka Brezniczky
Attila Laczovics
Ervin Berényi
Tamas Erdei
Oluwatofunmi Ojo
Bence Hornok
Bela Juhasz
Zoltan Szilvassy
Judit Zsuga

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1683950

952 views

Review

Published on 20 Oct 2025

An overview of insights and updates on TTN mutations in cardiomyopathies

in Cardiovascular and Smooth Muscle Pharmacology

Sarmistha Saha
Gazmend Temaj
Pelin Telkoparan-Akillilar
Silvia Chichiarelli
Luciano Saso

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1668544

2,063 views
1 citation

Original Research

Published on 20 Oct 2025

Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes

in Cardiovascular and Smooth Muscle Pharmacology

Edy Kornelius
Shih-Chang Lo
Yi-Sun Yang
Yu-Hsun Wang
Chien-Ning Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1686851

1,448 views

1,408 articles

articles

Case Report: Exercise-associated changes of leukocyte gene expression in statin-associated myopathy

Gallic acid attenuates diabetic cardiomyopathy by inhibiting ferroptosis and protecting mitochondria via the TSPO/FTMT pathway

Probucol: Revisiting as a Multi-faceted Therapeutic Agent in Atherosclerosis

Association between ranolazine therapy and cognitive decline in elderly patients with ischemic heart disease

Targeting L-arginine/NO/cGMP/KATP pathway by phytochemicals: therapeutic applications and clinical perspectives

The complications of cyclosporine a in pediatric use and its effectiveness in treating pediatric congenital heart diseases-a meta analysis in combined with a retrospective clinical study

Echocardiographic assessment and new advances of right ventricle function in rats with pulmonary hypertension

Jaranol: a compound with therapeutic activity against pathological cardiac remodelling via multi-target inhibition of the Snai3/TLR2 and NF-κB signaling pathways

Commentary: Hyperoside alleviates myocardial ischemia-reperfusion injury in heart transplantation by promoting mitochondrial fusion via activating the Stat3-Tom70-Opa1 pathway

Preventive effect of small molecule active substances on septic cardiomyopathy after abdominal trauma: A systematic review and meta-analysis

The potential mechanism of celastrol attenuating atherosclerosis by promoting macrophage autophagy via AMPK/ULK1 pathway

Endoplasmic reticulum oxidoreductin 1α as a potential therapeutic target in diseases: from oxidative protein folding to pathophysiological mechanisms

Terminal complement inhibition in atypical haemolytic uremic syndrome: a single-centre experience

Gut Microbiota-Dependent Anti-Inflammatory Mechanisms of Berberine in Ameliorating Hypertension: Role of SCFAs, LPS Reduction, and STAT3 Signaling

The unmet promise: a critical review of antioxidant strategies in myocardial ischemia-reperfusion injury and the path towards precision medicine

A novel bioactive peptide-peptoid hybrid of alpha-calcitonin gene-related peptide protects against pressure-overload induced heart failure

Rifampicin-induced challenges in managing endocrine hypertension and primary aldosteronism: a case report and literature review

Agonizing GABABR suppresses GLP-1RA’s chronotropic effect and reduces post-myocardial infarction arrhythmogenesis

Efficacy and influencing factors analysis of SGLT2 inhibitors in treating heart failure following acute myocardial infarction

Risk of post-polypectomy bleeding and thromboembolic events during colonoscopy in patients on continued or interrupted antiplatelet therapy: a pooled analysis

Quantitative assessment of the usability of electromechanical human-based modelling and simulation to replace Langendorff isolated rabbit heart experiments in the preclinical setting

The interaction of AB-680, a CD73 inhibitor, with NBTI, a nucleoside transporter inhibitor, on the adenosinergic control of atrial contractility

An overview of insights and updates on TTN mutations in cardiomyopathies

Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes